Myriad Genetics Stock Price, News & Analysis

Myriad Genetics (NASDAQ: MYGN) has announced early access to its FirstGene Multiple Prenatal Screen, a comprehensive prenatal genetic testing solution. The test combines multiple screening modalities into a single blood draw, eliminating the need for paternal testing. FirstGene will be launched through the CONNECTOR study, targeting over 5,000 patients across multiple clinical sites. The screen offers high accuracy with 98.6% sensitivity and 99.6% specificity, capable of identifying carrier status, fetal genetic anomalies, chromosomal aneuploidies, 22q11.2 microdeletion, pathogenic mutations in 10 recessive conditions, and RhD compatibility. This streamlined approach makes guideline-driven testing more accessible while representing a significant growth opportunity for Myriad in the prenatal testing market.

Myriad Genetics (MYGN) revealed promising clinical data from the MONSTAR-SCREEN-3 study for their Precise MRD Test, demonstrating 100% detection of circulating tumor DNA (ctDNA) at baseline across multiple cancer types. The study, conducted with Japan's National Cancer Center Hospital East, showed the test can detect tumor fractions as low as 0.0001% and successfully created personalized whole-genome sequencing panels for 97.3% of patients. Notably, 60% of ctDNA-positive patients one month post-surgery had ultra-low tumor fractions only detectable by Precise MRD's enhanced sensitivity. These patients showed significantly worse disease-free survival compared to ctDNA-negative patients. The test also demonstrated ability to predict pathological complete response during neoadjuvant chemotherapy and showed earlier recurrence detection compared to imaging.

Myriad Genetics (NASDAQ: MYGN) will present seven new research studies at the 2025 ASCO Annual Meeting, showcasing advancements in oncology and precision medicine. Key highlights include the MONSTAR-SCREEN-3 study, demonstrating successful pan-cancer implementation of whole genome sequencing-based personalized ctDNA detection, achieving 100% baseline detection across tumor types. The company announced upcoming product innovations including: Precise MRD Test (commercial launch in 2026), Prolaris Prostate Cancer Test with PATHOMIQ AI technology (early 2026), expanded MyRisk Hereditary Cancer Test panel (late 2025), and full EMR integration with Flatiron's OncoEMR and Epic platforms (late 2025). These developments reflect Myriad's commitment to advancing personalized cancer care through genetic and tumor genomic testing solutions.

Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has announced its participation in two major upcoming healthcare investor conferences. Management will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 6:00 PM ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 2:00 PM ET. Both presentations will be available for viewing through live and archived webcasts on the company's investor relations website at investor.myriad.com.

Myriad Genetics (NASDAQ: MYGN) announced the publication of a real-world study in JCO Precision Oncology demonstrating the effectiveness of their RiskScore® breast cancer risk assessment tool. The study showed that RiskScore predicted different risk levels than the Tyrer-Cuzick model for nearly 20% of patients. Notably, patients with ≥20% lifetime breast cancer risk identified by RiskScore were more likely to receive guidelines-aligned screening, including mammography, breast MRI, and genetic counseling.

RiskScore, which is integrated into Myriad's MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model to predict five-year and remaining lifetime breast cancer risk. The study findings suggest that clinicians are effectively utilizing RiskScore results to make informed decisions about patient risk management and screening recommendations.

Myriad Genetics (MYGN) reported challenging Q1 2025 results with revenue of $196 million, declining 3% year-over-year. Excluding $16M in headwinds, revenue grew 5%. The company's Prenatal segment showed 11% growth, while Pharmacogenomics revenue dropped 20% due to UnitedHealthcare reducing GeneSight® coverage. Test volumes reached 385,000, up 1% YoY. The company reported a minimal GAAP net loss of $0.1M ($0.00 EPS) and adjusted EPS of $(0.03). Myriad updated its 2025 guidance, lowering revenue expectations to $807-823 million from $840-860 million, and adjusted EPS to $(0.02)-$0.02 from $0.07-$0.11. The company maintains a strong liquidity position with $92 million in cash and access to an additional $42 million through its credit facility.

Myriad Genetics reveals significant findings about mental health medication perceptions through their GeneSight Mental Health Monitor survey. While 89% of Americans with depression/anxiety believe in medication effectiveness, 52% avoid taking them due to side effect concerns.

The survey highlights that 54% of patients believe genetic testing (pharmacogenomic/PGx testing) could reduce medication concerns. Notably, 62% of diagnosed patients whose providers didn't use PGx testing wish they had been informed about it.

The study also shows strong social acceptance of mental health medications, with 67% agreeing it's socially acceptable to take them, and 66% having positive views of others using such medications. Patients rate mental health medication effectiveness similarly to treatments for high blood pressure (94%), high cholesterol (90%), and arthritis (84%).

Myriad Genetics has scheduled its first quarter 2025 earnings conference call for May 6, 2025, at 4:30 pm EDT. The company will release its Q1 2025 financial results after market close on the same day.

Investors can access the live webcast through investor.myriad.com. To join via telephone, participants must register to receive a dial-in number and unique PIN.

Additionally, Myriad's management will participate in two major healthcare investor conferences:

• BofA Securities 2025 Health Care Conference - Fireside chat on May 14, 2025, at 3:00 pm EDT
• Goldman Sachs 46th Annual Global Healthcare Conference - Fireside chat on June 11, 2025, at 2:00 pm EDT

Both conference presentations will be available for viewing through live and archived webcasts on the company's investor relations website.

Myriad Genetics (NASDAQ: MYGN) announced new clinical data for their Precise™ MRD test in oligometastatic clear-cell renal cell carcinoma (ccRCC) patients at the AACR Annual Meeting. The study, presented by Dr. Chad Tang from MD Anderson Cancer Center, demonstrated that metastasis-directed radiation therapy helped patients delay or avoid systematic treatments while maintaining high survival rates of 94% at two years and 87% at three years.

The research showed that patients testing positive on Precise MRD initiated systemic therapy within a median of 27 months, while MRD-negative patients maintained on radiation therapy for 54 months. The test identified over 50% of patients as MRD-positive at baseline, demonstrating superior detection capabilities in ccRCC's challenging low tumor fractions compared to first-generation tests.

Additional research presented includes optimization of tumor-informed MRD panels and the benefits of including INDEL mutations for improved detection sensitivity. Precise MRD is currently available for research studies in partnership with academic and pharmaceutical investigators.